Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches

Redox Biology

Volumn 15, Issue , 2018, Pages 467-479

  Borrelli, Antonella ^a   Bonelli, Patrizia ^a   Tuccillo, Franca Maria ^a   Goldfine, Ira D ^b   Evans, Joseph L ^c   Buonaguro, Franco Maria ^a   Mancini, Aldo ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c P N Development Venture   (United States)

^d Leadhexa Biotechnologies Inc QB3 953   (United States)

Author keywords

Antioxidants; Drugs; Interventions; Manganese superoxide dismutase; Probiotics

Indexed keywords

ANTIOXIDANT; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE EXACERBATION; HUMAN; INCIDENCE; INTESTINE FLORA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PATIENT RISK; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MICROBIOLOGY; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 85041470124     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2018.01.009     Document Type: Review

References (194)

1. Paschos, P., Paletas, K., Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13 (2009), 9–19.
2. Bellentani, S., The epidemiology of non-alcoholic fatty liver disease. Liver Int. 37:Suppl. 1 (2017), S81–S84.
3. Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34 (2011), 274–285.
4. Do, A., Lim, J.K., Epidemiology of nonalcoholic fatty liver disease: a primer. Clin. Liver Dis. 7 (2016), 106–108.
5. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
6. Bellentani, S., Scaglioni, F., Marino, M., Bedogni, G., Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 28 (2010), 155–161.
7. Misra, V.L., Khashab, M., Chalasani, N., Nonalcoholic fatty liver disease and cardiovascular risk. Curr. Gastroenterol. Rep. 11 (2009), 50–55.
8. Lazo, M., Hernaez, R., Eberhardt, M.S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F.L., Clark, J.M., Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am. J. Epidemiol. 178 (2013), 38–45.
9. Chang, Y., Ryu, S., Sung, E., Jang, Y., Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin. Chem. 53 (2007), 686–692.
10. Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., Marchesini, G., A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53 (2010), 372–384.
11. Pereira, K., Salsamendi, J., Casillas, J., The global nonalcoholic fatty liver disease epidemic: what a radiologist needs to know. J. Clin. Imaging Sci., 5, 2015, 32.
12. Adami, H.O., Chow, W.H., Nyren, O., Berne, C., Linet, M.S., Ekbom, A., Wolk, A., McLaughlin, J.K., Fraumeni, J.F. Jr., Excess risk of primary liver cancer in patients with diabetes mellitus. J. Natl. Cancer Inst. 88 (1996), 1472–1477.
13. Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., Bellentani, S., Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005), 44–52.
14. Argo, C.K., Northup, P.G., Al-Osaimi, A.M., Caldwell, S.H., Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51 (2009), 371–379.
15. Ertle, J., Dechene, A., Sowa, J.P., Penndorf, V., Herzer, K., Kaiser, G., Schlaak, J.F., Gerken, G., Syn, W.K., Canbay, A., Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 128 (2011), 2436–2443.
16. Chagas, A.L., Kikuchi, L.O., Oliveira, C.P., Vezozzo, D.C., Mello, E.S., Oliveira, A.C., Cella, L.C., Herman, P., Bachella, T., Caldwell, S.H., Alves, V.A., Carrilho, F.J., Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?. Braz. J. Med. Biol. Res. 42 (2009), 958–962.
17. Sanyal, A.J., Banas, C., Sargeant, C., Luketic, V.A., Sterling, R.K., Stravitz, R.T., Shiffman, M.L., Heuman, D., Coterrell, A., Fisher, R.A., Contos, M.J., Mills, A.S., Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43 (2006), 682–689.
18. Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 (2014), 2188–2195.
19. Pagano, G., Pacini, G., Musso, G., Gambino, R., Mecca, F., Depetris, N., Cassader, M., David, E., Cavallo-Perin, P., Rizzetto, M., Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 (2002), 367–372.
20. Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (2010), 1836–1846.
21. Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits"?. Gastroenterology 114 (1998), 842–845.
22. Gentile, C.L., Pagliassotti, M.J., The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J. Nutr. Biochem. 19 (2008), 567–576.
23. Sumida, Y., Niki, E., Naito, Y., Yoshikawa, T., Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic. Res. 47 (2013), 869–880.
24. Abu-Shanab, A., Quigley, E.M., The role of the gut microbiota in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7 (2010), 691–701.
25. Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., Semenkovich, C.F., Gordon, J.I., The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101 (2004), 15718–15723.
26. Al-Busafi, S.A., Bhat, M., Wong, P., Ghali, P., Deschenes, M., Antioxidant therapy in nonalcoholic steatohepatitis. Hepat. Res. Treat., 2012, 2012, 947575.
27. Takaki, A., Kawai, D., Yamamoto, K., Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int. J. Mol. Sci. 14 (2013), 20704–20728.
28. Peverill, W., Powell, L.W., Skoien, R., Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int. J. Mol. Sci. 15 (2014), 8591–8638.
29. Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P.A., Moser, A.B., Desimone, C., Song, X.Y., Diehl, A.M., Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37 (2003), 343–350.
30. Clementi, A.H., Gaudy, A.M., van Rooijen, N., Pierce, R.H., Mooney, R.A., Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochim. Biophys. Acta 1792 (2009), 1062–1072.
31. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., Boerwinkle, E., Cohen, J.C., Hobbs, H.H., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40 (2008), 1461–1465.
32. Charlton, M., Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin. Gastroenterol. Hepatol. 2 (2004), 1048–1058.
33. Carbone, F., La Rocca, C., Matarese, G., Immunological functions of leptin and adiponectin. Biochimie 94 (2012), 2082–2088.
34. Polyzos, S.A., Toulis, K.A., Goulis, D.G., Zavos, C., Kountouras, J., Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60 (2011), 313–326.
35. Wolf, A.M., Wolf, D., Rumpold, H., Enrich, B., Tilg, H., Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 323 (2004), 630–635.
36. La Cava, A., Alviggi, C., Matarese, G., Unraveling the multiple roles of leptin in inflammation and autoimmunity. J. Mol. Med. 82 (2004), 4–11.
37. La Cava, A., Matarese, G., The weight of leptin in immunity. Nat. Rev. Immunol. 4 (2004), 371–379.
38. Nannipieri, M., Cecchetti, F., Anselmino, M., Mancini, E., Marchetti, G., Bonotti, A., Baldi, S., Solito, B., Giannetti, M., Pinchera, A., Santini, F., Ferrannini, E., Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes. Surg. 19 (2009), 467–474.
39. Ma, H., Gomez, V., Lu, L., Yang, X., Wu, X., Xiao, S.Y., Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 24 (2009), 233–237.
40. Bull, M.J., Plummer, N.T., Part 1: the human gut microbiome in health and disease. Integr. Med. 13 (2014), 17–22.
41. Gratz, S.W., Mykkanen, H., El-Nezami, H.S., Probiotics and gut health: a special focus on liver diseases. World J. Gastroenterol. 16 (2010), 403–410.
42. Zak-Golab, A., Olszanecka-Glinianowicz, M., Kocelak, P., Chudek, J., The role of gut microbiota in the pathogenesis of obesity. Post. Hig. Med. Dosw. 68 (2014), 84–90 (Online).
43. Preiss-Landl, K., Zimmermann, R., Hammerle, G., Zechner, R., Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr. Opin. Lipidol. 13 (2002), 471–481.
44. Valentini, M., Piermattei, A., Di Sante, G., Migliara, G., Delogu, G., Ria, F., Immunomodulation by gut microbiota: role of toll-like receptor expressed by T cells. J. Immunol. Res., 2014, 2014, 586939.
45. Kim, J.J., Sears, D.D., TLR4 and insulin resistance. Gastroenterol. Res. Pract., 2010, 2010.
46. Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A.M., Fava, F., Tuohy, K.M., Chabo, C., Waget, A., Delmee, E., Cousin, B., Sulpice, T., Chamontin, B., Ferrieres, J., Tanti, J.F., Gibson, G.R., Casteilla, L., Delzenne, N.M., Alessi, M.C., Burcelin, R., Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772.
47. Neal, M.D., Leaphart, C., Levy, R., Prince, J., Billiar, T.R., Watkins, S., Li, J., Cetin, S., Ford, H., Schreiber, A., Hackam, D.J., Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J. Immunol. 176 (2006), 3070–3079.
48. Wang, Y., Ghoshal, S., Ward, M., de Villiers, W., Woodward, J., Eckhardt, E., Chylomicrons promote intestinal absorption and systemic dissemination of dietary antigen (ovalbumin) in mice. PLoS One, 4, 2009, e8442.
49. Vreugdenhil, A.C., Rousseau, C.H., Hartung, T., Greve, J.W., van't Veer, C., Buurman, W.A., Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J. Immunol. 170 (2003), 1399–1405.
50. Brun, P., Castagliuolo, I., Di Leo, V., Buda, A., Pinzani, M., Palu, G., Martines, D., Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007), G518–G525.
51. Wright, S.D., Ramos, R.A., Tobias, P.S., Ulevitch, R.J., Mathison, J.C., CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 (1990), 1431–1433.
52. Beutler, B., Hoebe, K., Du, X., Ulevitch, R.J., How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. 74 (2003), 479–485.
53. Ruiz, A.G., Casafont, F., Crespo, J., Cayon, A., Mayorga, M., Estebanez, A., Fernadez-Escalante, J.C., Pons-Romero, F., Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 17 (2007), 1374–1380.
54. Brun, P., Castagliuolo, I., Pinzani, M., Palu, G., Martines, D., Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005), G571–G578.
55. Paik, Y.H., Schwabe, R.F., Bataller, R., Russo, M.P., Jobin, C., Brenner, D.A., Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37 (2003), 1043–1055.
56. Albano, E., Mottaran, E., Occhino, G., Reale, E., Vidali, M., Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment. Pharmacol. Ther. 22:Suppl. 2 (2005), S71–S73.
57. Albano, E., Mottaran, E., Vidali, M., Reale, E., Saksena, S., Occhino, G., Burt, A.D., Day, C.P., Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54 (2005), 987–993.
58. Seki, S., Kitada, T., Yamada, T., Sakaguchi, H., Nakatani, K., Wakasa, K., In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37 (2002), 56–62.
59. Begriche, K., Igoudjil, A., Pessayre, D., Fromenty, B., Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6 (2006), 1–28.
60. Jones, R.M., Neish, A.S., Redox signaling mediated by the gut microbiota. Free Radic. Biol. Med. 105 (2017), 41–47.
61. Kountouras, J., Boziki, M., Polyzos, S.A., Katsinelos, P., Gavalas, E., Zeglinas, C., Tzivras, D., Romiopoulos, I., Giorgakis, N., Anastasiadou, K., Vardaka, E., Kountouras, C., Kazakos, E., Xiromerisiou, G., Dardiotis, E., Deretzi, G., Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis. Free Radic. Res. 51 (2017), 73–79.
62. Doulberis, M., Kotronis, G., Gialamprinou, D., Kountouras, J., Katsinelos, P., Non-alcoholic fatty liver disease: an update with special focus on the role of gut microbiota. Metabolism 71 (2017), 182–197.
63. Purohit, V., Bode, J.C., Bode, C., Brenner, D.A., Choudhry, M.A., Hamilton, F., Kang, Y.J., Keshavarzian, A., Rao, R., Sartor, R.B., Swanson, C., Turner, J.R., Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 42 (2008), 349–361.
64. Setshedi, M., Wands, J.R., Monte, S.M., Acetaldehyde adducts in alcoholic liver disease. Oxid. Med. Cell. Longev. 3 (2010), 178–185.
65. Su, G.L., Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 283 (2002), G256–G265.
66. Gustot, T., Lemmers, A., Moreno, C., Nagy, N., Quertinmont, E., Nicaise, C., Franchimont, D., Louis, H., Deviere, J., Le Moine, O., Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 43 (2006), 989–1000.
67. Wieckowska, A., McCullough, A.J., Feldstein, A.E., Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46 (2007), 582–589.
68. Nassir, F., Ibdah, J.A., Role of mitochondria in nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15 (2014), 8713–8742.
69. Fritz, R., Bol, J., Hebling, U., Angermuller, S., Volkl, A., Fahimi, H.D., Mueller, S., Compartment-dependent management of H(2)O(2) by peroxisomes. Free Radic. Biol. Med. 42 (2007), 1119–1129.
70. Rolo, A.P., Teodoro, J.S., Palmeira, C.M., Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 52 (2012), 59–69.
71. Mittler, R., Vanderauwera, S., Suzuki, N., Miller, G., Tognetti, V.B., Vandepoele, K., Gollery, M., Shulaev, V., Van Breusegem, F., ROS signaling: the new wave?. Trends Plant Sci. 16 (2011), 300–309.
72. Turrens, J.F., Mitochondrial formation of reactive oxygen species. J. Physiol. 552 (2003), 335–344.
73. Nelson, J.E., Wilson, L., Brunt, E.M., Yeh, M.M., Kleiner, D.E., Unalp-Arida, A., Kowdley, K.V., Nonalcoholic Steatohepatitis Clinical Research, N., Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53 (2011), 448–457.
74. Ricci, C., Pastukh, V., Leonard, J., Turrens, J., Wilson, G., Schaffer, D., Schaffer, S.W., Mitochondrial, DNA damage triggers mitochondrial-superoxide generation and apoptosis. Am. J. Physiol. Cell Physiol. 294 (2008), C413–C422.
75. Picard, M., Pathways to aging: the mitochondrion at the intersection of biological and psychosocial sciences. J. Aging Res., 2011, 2011, 814096.
76. Scarpulla, R.C., Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta 1813 (2011), 1269–1278.
77. Aharoni-Simon, M., Hann-Obercyger, M., Pen, S., Madar, Z., Tirosh, O., Fatty liver is associated with impaired activity of PPARgamma-coactivator 1alpha (PGC1alpha) and mitochondrial biogenesis in mice. Lab. Invest. 91 (2011), 1018–1028.
78. Yoon, J.C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C.R., Granner, D.K., Newgard, C.B., Spiegelman, B.M., Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 (2001), 131–138.
79. Mardinoglu, A., Shoaie, S., Bergentall, M., Ghaffari, P., Zhang, C., Larsson, E., Backhed, F., Nielsen, J., The gut microbiota modulates host amino acid and glutathione metabolism in mice. Mol. Syst. Biol., 11, 2015, 834.
80. Kojer, K., Bien, M., Gangel, H., Morgan, B., Dick, T.P., Riemer, J., Glutathione redox potential in the mitochondrial intermembrane space is linked to the cytosol and impacts the Mia40 redox state. EMBO J. 31 (2012), 3169–3182.
81. Morgan, B., Ezerina, D., Amoako, T.N., Riemer, J., Seedorf, M., Dick, T.P., Multiple glutathione disulfide removal pathways mediate cytosolic redox homeostasis. Nat. Chem. Biol. 9 (2013), 119–125.
82. Davila, A.M., Blachier, F., Gotteland, M., Andriamihaja, M., Benetti, P.H., Sanz, Y., Tome, D., Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host. Pharmacol. Res. 68 (2013), 95–107.
83. Sanyal, D., Mukherjee, P., Raychaudhuri, M., Ghosh, S., Mukherjee, S., Chowdhury, S., Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J. Endocrinol. Metab. 19 (2015), 597–601.
84. Grattagliano, I., Portincasa, P., Palmieri, V.O., Palasciano, G., Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can. Fam. Phys. 53 (2007), 857–863.
85. Portincasa, P., Grattagliano, I., Palmieri, V.O., Palasciano, G., The emerging problem of nonalcoholic steatohepatitis (NASH). Rom. J. Gastroenterol. 14 (2005), 43–51.
86. Portincasa, P., Grattagliano, I., Palmieri, V.O., Palasciano, G., Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin. Biochem. 38 (2005), 203–217.
87. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., Sanyal, A.J., Nonalcoholic Steatohepatitis Clinical Research, N., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
88. Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P., Neuschwander-Tetri, B.A., Network, N.C.R., Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820.
89. Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., Mills, P.R., Keach, J.C., Lafferty, H.D., Stahler, A., Haflidadottir, S., Bendtsen, F., liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 (e310).
90. Alkhouri, N., Berk, M., Yerian, L., Lopez, R., Chung, Y.M., Zhang, R., McIntyre, T.M., Feldstein, A.E., Hazen, S.L., OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig. Dis. Sci. 59 (2014), 1617–1624.
91. Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., Pol, S., FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46 (2007), 32–36.
92. Castera, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., De Ledinghen, V., Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005), 343–350.
93. van Katwyk, S., Coyle, D., Cooper, C., Pussegoda, K., Cameron, C., Skidmore, B., Brener, S., Moher, D., Thavorn, K., Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations. Liver Int. 37 (2017), 851–861.
94. Masuzaki, R., Tateishi, R., Yoshida, H., Goto, E., Sato, T., Ohki, T., Goto, T., Yoshida, H., Kanai, F., Sugioka, Y., Ikeda, H., Shiina, S., Kawabe, T., Omata, M., Comparison of liver biopsy and transient elastography based on clinical relevance. Can. J. Gastroenterol. 22 (2008), 753–757.
95. Musso, G., Gambino, R., Cassader, M., Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes. Rev. 11 (2010), 430–445.
96. Oseini, A.M., Sanyal, A.J., Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 37 (2017), 97–103.
97. Cani, P.D., Delzenne, N.M., The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Des. 15 (2009), 1546–1558.
98. Ma, X., Hua, J., Li, Z., Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J. Hepatol. 49 (2008), 821–830.
99. Seki, S., Habu, Y., Kawamura, T., Takeda, K., Dobashi, H., Ohkawa, T., Hiraide, H., The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol. Rev. 174 (2000), 35–46.
100. Collins, M.D., Gibson, G.R., Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am. J. Clin. Nutr. 69 (1999), 1052S–1057S.
101. Usami, M., Miyoshi, M., Yamashita, H., Gut microbiota and host metabolism in liver cirrhosis. World J. Gastroenterol. 21 (2015), 11597–11608.
102. Sanders, M.E., Guarner, F., Guerrant, R., Holt, P.R., Quigley, E.M., Sartor, R.B., Sherman, P.M., Mayer, E.A., An update on the use and investigation of probiotics in health and disease. Gut 62 (2013), 787–796.
103. Slavin, J., Fiber and prebiotics: mechanisms and health benefits. Nutrients 5 (2013), 1417–1435.
104. Lata, J., Jurankova, J., Kopacova, M., Vitek, P., Probiotics in hepatology. World J. Gastroenterol. 17 (2011), 2890–2896.
105. Jonkers, D., Stockbrugger, R., Review article: probiotics in gastrointestinal and liver diseases. Aliment. Pharmacol. Ther. 26:Suppl. 2 (2007), S133–S148.
106. Soriano, G., Sanchez, E., Guarner, C., Schiffrin, E.J., Lactobacillus johnsonii La1 without antioxidants does not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. J. Hepatol. 57 (2012), 1395–1396.
107. Usami, M., Miyoshi, M., Kanbara, Y., Aoyama, M., Sakaki, H., Shuno, K., Hirata, K., Takahashi, M., Ueno, K., Tabata, S., Asahara, T., Nomoto, K., Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or without cirrhosis. JPEN J. Parenter. Enter. Nutr. 35 (2011), 317–328.
108. Blendis, L., Wong, F., The hyperdynamic circulation in cirrhosis: an overview. Pharmacol. Ther. 89 (2001), 221–231.
109. Liu, Q., Duan, Z.P., Ha, D.K., Bengmark, S., Kurtovic, J., Riordan, S.M., Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39 (2004), 1441–1449.
110. Agrawal, A., Sharma, B.C., Sharma, P., Sarin, S.K., Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am. J. Gastroenterol. 107 (2012), 1043–1050.
111. Bajaj, J.S., Saeian, K., Christensen, K.M., Hafeezullah, M., Varma, R.R., Franco, J., Pleuss, J.A., Krakower, G., Hoffmann, R.G., Binion, D.G., Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am. J. Gastroenterol. 103 (2008), 1707–1715.
112. Malaguarnera, M., Gargante, M.P., Malaguarnera, G., Salmeri, M., Mastrojeni, S., Rampello, L., Pennisi, G., Li Volti, G., Galvano, F., Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 22 (2010), 199–206.
113. Tandon, P., Moncrief, K., Madsen, K., Arrieta, M.C., Owen, R.J., Bain, V.G., Wong, W.W., Ma, M.M., Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int. 29 (2009), 1110–1115.
114. McGee, R.G., Bakens, A., Wiley, K., Riordan, S.M., Webster, A.C., Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst. Rev., 2011, CD008716.
115. Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K., Mandrekar, P., Szabo, G., VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49 (2009), 989–997.
116. Loguercio, C., Federico, A., Tuccillo, C., Terracciano, F., D'Auria, M.V., De Simone, C., Del Vecchio Blanco, C., Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 39 (2005), 540–543.
117. Gupta, N., Kumar, A., Sharma, P., Garg, V., Sharma, B.C., Sarin, S.K., Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int. 33 (2013), 1148–1157.
118. Pande, C., Kumar, A., Sarin, S.K., Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial. Eur. J. Gastroenterol. Hepatol. 24 (2012), 831–839.
119. Musso, G., Cassader, M., Rosina, F., Gambino, R., Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55 (2012), 885–904.
120. Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., Portillo-Sanchez, P., Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165 (2016), 305–315.
121. Neumann, A., Weill, A., Ricordeau, P., Fagot, J.P., Alla, F., Allemand, H., Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 55 (2012), 1953–1962.
122. Bourg, C.A., Phillips, B.B., Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann. Pharmacother. 46 (2012), 282–289.
123. Molavi, B., Rassouli, N., Bagwe, S., Rasouli, N., A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc. Health Risk Manag. 3 (2007), 967–973.
124. Sokol, R.J., McKim, J.M. Jr, Goff, M.C., Ruyle, S.Z., Devereaux, M.W., Han, D., Packer, L., Everson, G., Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 114 (1998), 164–174.
125. Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., Lavine, J.E., Tonascia, J., Unalp, A., Van Natta, M., Clark, J., Brunt, E.M., Kleiner, D.E., Hoofnagle, J.H., Robuck, P.R., Nash, C.R.N., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362 (2010), 1675–1685.
126. Klein, E.A., Thompson, I.M. Jr., Tangen, C.M., Crowley, J.J., Lucia, M.S., Goodman, P.J., Minasian, L.M., Ford, L.G., Parnes, H.L., Gaziano, J.M., Karp, D.D., Lieber, M.M., Walther, P.J., Klotz, L., Parsons, J.K., Chin, J.L., Darke, A.K., Lippman, S.M., Goodman, G.E., Meyskens, F.L. Jr., Baker, L.H., vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (select). JAMA 306 (2011), 1549–1556.
127. de Freitas, A.C., Campos, A.C., Coelho, J.C., The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care 11 (2008), 267–274.
128. Rabl, C., Campos, G.M., The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin. Liver Dis. 32 (2012), 80–91.
129. Lim, J.K., The role of bariatric surgery in the management of nonalcoholic steatohepatitis. Gastroenterol. Hepatol. 12 (2016), 397–399.
130. Gerhard, G.S., DiStefano, J.K., Micro RNAs in the development of non-alcoholic fatty liver disease. World J. Hepatol. 7 (2015), 226–234.
131. Jani, R.H., Kansagra, K., Jain, M.R., Patel, H., Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin. Drug Investig. 33 (2013), 809–816.
132. Liles, J.T., Karnik, S., Hambruch, E., Kremoser, C., Birkel, M., Watkins, W.J., Tumas, D., Breckenridge, D., French, D., Fxr agonism by Gs-9674 decreases steatosis and fibrosis in a murine model of nash. J. Hepatol., 64, 2016, S169.
133. Dong, J.Q., Rossulek, M., Somayaji, V.R., Baltrukonis, D., Liang, Y., Hudson, K., Hernandez-Illas, M., Calle, R.A., Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br. J. Clin. Pharmacol. 80 (2015), 1051–1063.
134. G. Wettstein, C. Estivalet, J. Tessier, P.T. Boustugue, I. Jantzen, E. Defrene, F. Kupkowski, P. Faye, V. Adarbes, J.M. Germain, E. Vasseur, C. Robert, C. Fromond, P. Broqua, J.L. Junien, J.M. Luccarini, I. Konstantinova, The new generation Pan-Ppar agonist Iva337 protects the liver from metabolic disorders and fibrosis, J. Hepatol., 64, pp. S169–S170.
135. Hegade, V.S., Speight, R.A., Etherington, R.E., Jones, D.E., Novel bile acid therapeutics for the treatment of chronic liver diseases. Ther. Adv. Gastroenterol. 9 (2016), 376–391.
136. Mousa, H.S., Lleo, A., Invernizzi, P., Bowlus, C.L., Gershwin, M.E., Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin. Pharmacother. 16 (2015), 633–643.
137. Wu, X., Ge, H., Lemon, B., Vonderfecht, S., Weiszmann, J., Hecht, R., Gupte, J., Hager, T., Wang, Z., Lindberg, R., Li, Y., FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. 285 (2010), 5165–5170.
138. Safadi, R., Konikoff, F.M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., Oren, R., Group, F., The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12 (2014), 2085–2091 (e2081).
139. Miethke, A.G., Zhang, W., Simmons, J., Taylor, A.E., Shi, T., Shanmukhappa, S.K., Karns, R., White, S., Jegga, A.G., Lages, C.S., Nkinin, S., Keller, B.T., Setchell, K.D., Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 63 (2016), 512–523.
140. Rao, A., Kosters, A., Mells, J.E., Zhang, W., Setchell, K.D., Amanso, A.M., Wynn, G.M., Xu, T., Keller, B.T., Yin, H., Banton, S., Jones, D.P., Wu, H., Dawson, P.A., Karpen, S.J., Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci. Transl. Med., 8, 2016, 357ra122.
141. Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., Hazlehurst, J.M., Guo, K., L.t. team, Abouda, G., Aldersley, M.A., Stocken, D., Gough, S.C., Tomlinson, J.W., Brown, R.M., Hubscher, S.G., Newsome, P.N., Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
142. Ratziu, V., Harrison, S.A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., Drenth, J., Anstee, Q.M., Hum, D., Hanf, R., Roudot, A., Megnien, S., Staels, B., Sanyal, A., Group, G.-I.S., Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150 (2016), 1147–1159 (e1145).
143. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., Dasarathy, S., Diehl, A.M., Hameed, B., Kowdley, K.V., McCullough, A., Terrault, N., Clark, J.M., Tonascia, J., Brunt, E.M., Kleiner, D.E., Doo, E., Network, N.C.R., Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
144. Mudaliar, S., Henry, R.R., Sanyal, A.J., Morrow, L., Marschall, H.U., Kipnes, M., Adorini, L., Sciacca, C.I., Clopton, P., Castelloe, E., Dillon, P., Pruzanski, M., Shapiro, D., Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 574–582 (e571).
145. Friedman, S., Sanyal, A., Goodman, Z., Lefebvre, E., Gottwald, M., Fischer, L., Ratziu, V., Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design. Contemp. Clin. Trials 47 (2016), 356–365.
146. Godoy, A.L., Rocha, A., da Silva Souza, C., Lanchote, V.L., Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients. J. Clin. Pharmacol. 56 (2016), 567–575.
147. Cui, J., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J., Haufe, W., Hooker, C., Brenner, D.A., Sirlin, C.B., Loomba, R., Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J. Hepatol. 65 (2016), 369–376.
148. McCormack, P.L., Evogliptin: first global approval. Drugs 75 (2015), 2045–2049.
149. Schilter, H.C., Collison, A., Russo, R.C., Foot, J.S., Yow, T.T., Vieira, A.T., Tavares, L.D., Mattes, J., Teixeira, M.M., Jarolimek, W., Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. Respir. Res., 16, 2015, 42.
150. Lin, J.H., Zhang, J.J., Lin, S.L., Chertow, G.M., Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron 129 (2015), 29–33.
151. Hardy, T., Anstee, Q.M., Day, C.P., Nonalcoholic fatty liver disease: new treatments. Curr. Opin. Gastroenterol. 31 (2015), 175–183.
152. Harrison, S.A., Marri, S.R., Chalasani, N., Kohli, R., Aronstein, W., Thompson, G.A., Irish, W., Miles, M.V., Xanthakos, S.A., Lawitz, E., Noureddin, M., Schiano, T.D., Siddiqui, M., Sanyal, A., Neuschwander-Tetri, B.A., Traber, P.G., Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment. Pharmacol. Ther. 44 (2016), 1183–1198.
153. Barreyro, F.J., Holod, S., Finocchietto, P.V., Camino, A.M., Aquino, J.B., Avagnina, A., Carreras, M.C., Poderoso, J.J., Gores, G.J., The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 35 (2015), 953–966.
154. Filozof, C., Goldstein, B.J., Williams, R.N., Sanyal, A., Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 75 (2015), 1373–1392.
155. W. Jarolimek B. Charlton LP22: phase 1 results from PXS-4728A, a selective SSAO/VAP-1 inhibitor, for the treatment of non-alcoholic steatohepatitis J. Hepatol. 62 S274 S275.
156. Weston, C.J., Shepherd, E.L., Claridge, L.C., Rantakari, P., Curbishley, S.M., Tomlinson, J.W., Hubscher, S.G., Reynolds, G.M., Aalto, K., Anstee, Q.M., Jalkanen, S., Salmi, M., Smith, D.J., Day, C.P., Adams, D.H., Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J. Clin. Invest. 125 (2015), 501–520.
157. Ohsawa, I., Ishikawa, M., Takahashi, K., Watanabe, M., Nishimaki, K., Yamagata, K., Katsura, K., Katayama, Y., Asoh, S., Ohta, S., Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 13 (2007), 688–694.
158. Liao, J.K., Linking endothelial dysfunction with endothelial cell activation. J. Clin. Invest. 123 (2013), 540–541.
159. Halliwell, B., Antioxidants: the basics–what they are and how to evaluate them. Adv. Pharmacol. 38 (1997), 3–20.
160. Domann, F.E., Aberrant free radical biology is a unifying theme in the etiology and pathogenesis of major human diseases. Int. J. Mol. Sci. 14 (2013), 8491–8495.
161. Borrelli, A., Schiattarella, A., Mancini, R., Pica, A., Pollio, M.L., Ruggiero, M.G., Bonelli, P., De Luca, V., Tuccillo, F.M., Capasso, C., Gori, E., Sanseverino, M., Carpentieri, A., Birolo, L., Pucci, P., Rommelaere, J., Mancini, A., A new hexapeptide from the leader peptide of rMnSOD enters cells through the oestrogen receptor to deliver therapeutic molecules. Sci. Rep., 6, 2016, 18691.
162. Wan, X.S., Devalaraja, M.N., St Clair, D.K., Molecular structure and organization of the human manganese superoxide dismutase gene. DNA Cell Biol. 13 (1994), 1127–1136.
163. Folz, R.J., Guan, J., Seldin, M.F., Oury, T.D., Enghild, J.J., Crapo, J.D., Mouse extracellular superoxide dismutase: primary structure, tissue-specific gene expression, chromosomal localization, and lung in situ hybridization. Am. J. Respir. Cell Mol. Biol. 17 (1997), 393–403.
164. Wispe, J.R., Clark, J.C., Burhans, M.S., Kropp, K.E., Korfhagen, T.R., Whitsett, J.A., Synthesis and processing of the precursor for human mangano-superoxide dismutase. Biochim. Biophys. Acta 994 (1989), 30–36.
165. Marberger, H., Huber, W., Bartsch, G., Schulte, T., Swoboda, P., Orgotein: a new antiinflammatory metalloprotein drug evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract. Int. Urol. Nephrol. 6 (1974), 61–74.
166. Emerit, J., Michelson, A.M., Robert, H.G., Chomette, G., Guerin, R.A., Blondon, J., Bertrand, M., Superoxide dismutase treatment of 2 cases of radiation-induced sclerosis. Sem. Hop. 59 (1983), 277–281.
167. Land, W., Schneeberger, H., Schleibner, S., Illner, W.D., Abendroth, D., Rutili, G., Arfors, K.E., Messmer, K., The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 57 (1994), 211–217.
168. Brazier, M.W., Doctrow, S.R., Masters, C.L., Collins, S.J., A manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion disease. Free Radic. Biol. Med. 45 (2008), 184–192.
169. Dhar, S.K., St Clair, D.K., Manganese superoxide dismutase regulation and cancer. Free Radic. Biol. Med. 52 (2012), 2209–2222.
170. Weydert, C., Roling, B., Liu, J., Hinkhouse, M.M., Ritchie, J.M., Oberley, L.W., Cullen, J.J., Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol. Cancer Ther. 2 (2003), 361–369.
171. Oberley, L.W., Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed. Pharmacother. 59 (2005), 143–148.
172. Borrelli, A., Schiattarella, A., Bonelli, P., Tuccillo, F.M., Buonaguro, F.M., Mancini, A., The functional role of MnSOD as a biomarker of human diseases and therapeutic potential of a new isoform of a human recombinant MnSOD. Biomed. Res. Int., 2014, 2014, 476789.
173. McCord, J.M., Edeas, M.A., SOD, oxidative stress and human pathologies: a brief history and a future vision. Biomed. Pharmacother. 59 (2005), 139–142.
174. Mancini, A., Borrelli, A., Schiattarella, A., Fasano, S., Occhiello, A., Pica, A., Sehr, P., Tommasino, M., Nuesch, J.P., Rommelaere, J., Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line. Int. J. Cancer 119 (2006), 932–943.
175. Mancini, A., Borrelli, A., Formisano, S., Masucci, M.T., Maffeo, A., Perla, G., De Martino, L., Bevilacqua, N., Botti, G., Maggino, T., Establishment and growth regulation of a novel ovarian cancer cell line from a poorly-differentiated adenocarcinoma: proposal for a new treatment. Eur. J. Gynaecol. Oncol. 20 (1999), 45–52.
176. Pisani, A., Sabbatini, M., Riccio, E., Rossano, R., Andreucci, M., Capasso, C., De Luca, V., Carginale, V., Bizzarri, M., Borrelli, A., Schiattarella, A., Santangelo, M., Mancini, A., Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. Clin. Exp. Nephrol. 18 (2014), 424–431.
177. Guillaume, M., Rodriguez-Vilarrupla, A., Gracia-Sancho, J., Rosado, E., Mancini, A., Bosch, J., Garcia-Pagan, J.C., Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. J. Hepatol. 58 (2013), 240–246.
178. Gracia-Sancho, J., Lavina, B., Rodriguez-Vilarrupla, A., Garcia-Caldero, H., Fernandez, M., Bosch, J., Garcia-Pagan, J.C., Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 47 (2008), 1248–1256.
179. Hide, D., Ortega-Ribera, M., Fernandez-Iglesias, A., Fondevila, C., Salvado, M.J., Arola, L., Garcia-Pagan, J.C., Mancini, A., Bosch, J., Gracia-Sancho, J., A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. Clin. Sci. 127 (2014), 527–537.
180. Mancini, A., Borrelli, A., Schiattarella, A., Aloj, L., Aurilio, M., Morelli, F., Pica, A., Occhiello, A., Lorizio, R., Mancini, R., Sica, A., Mazzarella, L., Sica, F., Grieco, P., Novellino, E., Pagnozzi, D., Pucci, P., Rommelaere, J., Biophysical and biochemical characterization of a liposarcoma-derived recombinant MnSOD protein acting as an anticancer agent. Int. J. Cancer 123 (2008), 2684–2695.
181. Borrelli, A., Schiattarella, A., Mancini, R., Morelli, F., Capasso, C., De Luca, V., Gori, E., Mancini, A., The leader peptide of a human rec. MnSOD as molecular carrier which delivers high amounts of Cisplatin into tumor cells inducing a fast apoptosis in vitro. Int. J. Cancer 128 (2011), 453–459.
182. Porter, L.E., Elm, M.S., Van Thiel, D.H., Eagon, P.K., Hepatic estrogen receptor in human liver disease. Gastroenterology 92 (1987), 735–745.
183. Melegari, M., Scaglioni, P.P., Mao, G.P., Pasquinelli, C., Baldini, G., Estrogen receptors in the human liver. Medicina 10 (1990), 154–157.
184. Shimizu, I., Impact of oestrogens on the progression of liver disease. Liver Int. 23 (2003), 63–69.
185. Matic, M., Bryzgalova, G., Gao, H., Antonson, P., Humire, P., Omoto, Y., Portwood, N., Pramfalk, C., Efendic, S., Berggren, P.O., Gustafsson, J.A., Dahlman-Wright, K., Estrogen signalling and the metabolic syndrome: targeting the hepatic estrogen receptor alpha action. PLoS One, 8, 2013, e57458.
186. Pan, H., Marsh, J.N., Christenson, E.T., Soman, N.R., Ivashyna, O., Lanza, G.M., Schlesinger, P.H., Wickline, S.A., Postformulation peptide drug loading of nanostructures. Methods Enzymol. 508 (2012), 17–39.
187. Egusquiaguirre, S.P., Igartua, M., Hernandez, R.M., Pedraz, J.L., Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin. Transl. Oncol. 14 (2012), 83–93.
188. Paulo, C.S., Pires das Neves, R., Ferreira, L.S., Nanoparticles for intracellular-targeted drug delivery. Nanotechnology, 22, 2011, 494002.
189. Hogg, R.T., Thorpe, P., Gerard, R.D., Retargeting adenoviral vectors to improve gene transfer into tumors. Cancer Gene Ther. 18 (2011), 275–287.
190. Kaneda, Y., Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin. Drug Deliv. 7 (2010), 1079–1093.
191. Namiki, Y., Fuchigami, T., Tada, N., Kawamura, R., Matsunuma, S., Kitamoto, Y., Nakagawa, M., Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Acc. Chem. Res. 44 (2011), 1080–1093.
192. Zhai, X., Huang, W., Liu, J., Pang, Y., Zhu, X., Zhou, Y., Yan, D., Micelles from amphiphilic block copolyphosphates for drug delivery. Macromol. Biosci. 11 (2011), 1603–1610.
193. Pasquetto, M.V., Vecchia, L., Covini, D., Digilio, R., Scotti, C., Targeted drug delivery using immunoconjugates: principles and applications. J. Immunother. 34 (2011), 611–628.
194. Liu, K., Wang, X., Fan, W., Zhu, Q., Yang, J., Gao, J., Gao, S., Degradable polyethylenimine derivate coupled to a bifunctional peptide R13 as a new gene-delivery vector. Int. J. Nanomed. 7 (2012), 1149–1162.